ClinicalTrials.gg
TerminatedNCT04021368Updated Sep 18, 2026

RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome

A Phase 1 interventional study of RVU120(SEL120) in Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome, sponsored by Ryvu Therapeutics SA. Terminated at 10 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-18.

Sponsored by Ryvu Therapeutics SA · Phase 1, Interventional, and Treatment

Why this study was terminated
RPD2 has been identified

From the registry’s dates

  • Primary completion was May 2024, 2 years 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
51
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 2,137 studies in Leukemia, Myeloid, Acute with a site in United States — 312 open to participants now, 466 under way, 24 of them phase 3. Leukemia, Myeloid, Acute · United States.

Enrollment
664th of 1,907
51 · median 35
Started
2019
with 90 others
Phase 1
772 of 2,137
130 open now
Registered
1,588th of 2,137
by date

Among the 2,137 studies in Leukemia, Myeloid, Acute with a site in United States, this one is the 664th largest by enrollment of the 1,907 interventional ones that give a count, is one of 91 that started in 2019, is one of 772 in phase 1, and was the 1,588th registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 816 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

312 of the 2,137 studies in Leukemia, Myeloid, Acute with a site in United States are open now. Recruiting first, the newest first:

307 more — sign in →

All 312 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,137 studies in Leukemia, Myeloid, Acute with a site in United States, or all of them as a file.
02

Study summary

This first-in-human study will evaluate RVU120 (SEL120), a novel small molecule CDK8/19 inhibitor, in patients with Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (HR-MDS), in terms of selection of the recommended dose for further clinical development and assessment of safety, tolerability, preliminary anti-leukemic activity, as well as pharmacokinetic and pharmacodynamic profiles.

Read the detailed description

The study will determine the recommended phase II dose (RP2D) and safety of RVU120 (SEL120) given as monotherapy over a range of dose-levels, following a closely controlled dose escalation study design.

03

Conditions studied

  • Acute Myeloid Leukemia
  • High-risk Myelodysplastic Syndrome

Keywords

  • Acute Myeloid Leukemia
  • Myelodysplastic Syndrome
  • CDK8/19 Inhibitor
  • RVU120 (SEL120)
  • Clinical Trial, Phase Ib
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All the following criteria must be met for a patient to be eligible for the study:

  1. Written provided prior to any study-related procedure.
  2. Age ≥18 years.
  3. AML diagnosis according to the 2016 World Health Organisation (WHO) classification (Arber et al. 2016) with disease with no available therapy who have exhausted the applicable standard of care; or Myelodysplastic Syndrome (MDS) diagnosis according to the 2016 WHO classification (Arber et al. 2016) with high-risk disease per the Revised International Prognostic Scoring System (IPSS-R >4.5) and with relapsed or refractory disease with no available therapy who have exhausted the applicable standard of care.
  4. (ECOG) performance score of 0-2.
  5. Patients must have been off anti-cancer treatment prior to study.
  6. Patients must have recovered from the toxic effects of previous treatments.
  7. Peripheral white blood cell (WBC) count \<10x10\^9/L; count >10,000/μL; Serum albumin ≥ 30g/L (3.0g/dL); Normal coagulation (elevated , prothrombin time or APTT \<1.3 x acceptable); and ALT ≤3x ULN; Total ≤1.5 x ULN; ≥60 mL/min (Cockcroft-Gault formula);
  8. Adequate cardiac function
  9. of at least 12 weeks.
  10. For females of (FCBP), a negative pregnancy test must be confirmed before enrolment. FCBP must commit to use a highly effective method of during study participation and until 6 months after the last dose of study drug. Females must also refrain from donating blood or egg (ovum) during the same time period.
  11. For males, an effective barrier method of contraception must be used during study participation until 6 months after the last dose of study drug, if the patient is sexually active with a FCBP. Males must also refrain from donating blood or sperm during the same time-period.
  12. Investigator considers the patient to be suitable for participation in the clinical study

Exclusion criteria

Exclusion Criteria:

  1. Active central nervous system (CNS) leukemia.
  2. Previous treatment with CDK8-targeted therapy.
  3. Patients who have undergone major surgery within 28 days prior to first dose of study drug.
  4. Hematopoietic stem cell transplant within 120 days prior to first dose of study drug.
  5. Active acute (GVHD)
  6. Infections and acute inflammatory conditions
  7. Known seropositivity or history of
  8. Known positive test of / or known active diagnosis of COVID-19 viral infection
  9. Ongoing significant liver disease
  10. Impairment of gastrointestinal function or gastrointestinal disease
  11. Ongoing drug-induced pneumonitis.
  12. Concurrent participation in another clinical trial.
  13. Taking any medications, herbal supplements or other substances (including smoking) that are known to be strong inhibitors or inducers of CYP1A2 or that can prolong Q wave to T wave () interval and/or cause torsade de pointes within less than 5 half-lives, prior to first dose of study drug.
  14. Significant cardiac dysfunction or poorly controlled angina.
  15. Currently taking drugs that are documented, in the drug package insert, to have a risk of causing prolonged QTc or torsades de pointes (TdP) within 5 half-lives prior to first dose of study drug.
  16. Personal or family history of serious ventricular arrhythmia, or QT interval corrected for heart rate (QTc) ≥470 ms (Bazett's formula).
  17. Any other prior or current medical condition or extenuating circumstance that, in the Investigator's opinion, could jeopardize patient safety or interfere with the objectives of the study.
  18. Prior history of other than AML or MDS, unless the patient has been free of the disease for 5 years or more prior to Screening.
  19. Pregnant or breast-feeding females.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
51 participants (actual)

Study arms

  • Experimental
    RVU120(SEL120)

    The first part of the study consists of dose-escalation cohorts where patients will receive ascending doses of RVU120(SEL120) to determine the recommended dose (RD) for further clinical development. The second part of the study is an enrichment cohort where additional 6 to 20 patients will be treated with RVU120(SEL120) to support the evaluation of the RD.

    Drug: RVU120(SEL120)

Interventions

  • RVU120(SEL120) will be administered as a single oral dose every other day (q.o.d.) for a total of 7 doses i.e. on Days 1, 3, 5, 7, 9, 11 and 13, in a 3-week treatment cycle.

06

What researchers measure

Primary outcomes

  1. Recommended dose (RD)

    The RD will be determined using all available data, which will include dose limiting toxicities (DLTs) and other toxicities, signs of anti-leukemic activity, pharmacokinetic and pharmacodynamic characteristics.

    Time frame: Up to 2 years

  2. Incidence of Adverse Events (Safety and Tolerability)

    Safety and tolerability profile will be assessed by Common Terminology Criteria for Adverse Events v5.0 and summarized by type, frequency, and severity of adverse events.

    Time frame: Up to 2 years

Secondary outcomes

  1. The Maximum Observed Concentration (C[max])

    Pharmacokinetic profile of RVU120(SEL120) will be characterized using the Maximum Observed Concentration (C\[max\]).

    Time frame: Up to 2 years

  2. The Terminal Half-life (t[1/2])

    Pharmacokinetic profile of RVU120(SEL120) will be characterized using the Terminal Half-life (t\[1/2\]).

    Time frame: Up to 2 years

  3. The Area Under the Curve (AUC)

    Pharmacokinetic profile of RVU120(SEL120) will be characterized using the Area Under the Curve (AUC).

    Time frame: Up to 2 years

  4. The Volume of Distribution at Steady State (Vss)

    Pharmacokinetic profile of RVU120(SEL120) will be characterized using the Volume of Distribution at Steady State (Vss).

    Time frame: Up to 2 years

  5. Anti-leukemic activity

    Anti-leukemic activity will be assessed by AML or MDS Response Criteria (Döhner et al., 2017, or Cheson et al., 2006, respectively).

    Time frame: Up to 2 years

Other outcomes

  1. AML surface markers

    Pharmacodynamic profile of RVU120(SEL120) will be characterized using immunophenotyping of AML surface markers by exploratory assay.

    Time frame: Up to 2 years

  2. Phosphorylated protein levels in AML blasts

    Pharmacodynamic profile of RVU120(SEL120) will be characterized using phosphorylated protein levels in AML blasts by exploratory immunoassay.

    Time frame: Up to 2 years

  3. Transcriptomic profile changes in AML blasts

    Pharmacodynamic profile of RVU120(SEL120) will be characterized using transcriptomic profile changes in AML blasts by exploratory next generation sequencing.

    Time frame: Up to 2 years

  4. Genetic profile changes in AML blasts

    Pharmacodynamic profile of RVU120(SEL120) will be characterized using genetic profile changes in AML blasts by next generation sequencing.

    Time frame: Up to 2 years

07

Study locations

10 sites
  • Sylvester Comprehensive Cancer Center, University of Miami Hospital and Clinics
    Miami, Florida 33136, United States
  • Northside Hospital
    Atlanta, Georgia 30342, United States
  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
  • Tennessee Oncology
    Nashville, Tennessee 37203, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Uniwersyteckie Centrum Kliniczne
    Gdansk, 80-214, Poland
  • MICS Centrum Medyczne Toruń
    Torun, 87-100, Poland
  • Instytut Hematologii i Transfuzjologii
    Warsaw, 02-776, Poland
  • Dolnośląskie Centrum Onkologii, Pulmonologii i Hematologii
    Wroclaw, 53-413, Poland
  • Świętokrzyskie Centrum Onkologii, Klinika Hematologii i Transplantacji Szpiku
    Kielce, Świętokrzyskie Voivodeship 25-734, Poland
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2019 to primary completion in May 2024, 56 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 12, 2019
First posted
Jul 16, 2019
StartActual
Sep 4, 2019
Primary completionActual
May 21, 2024
CompletionActual
May 21, 2024
Last update
Sep 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04021368
Lead sponsor
Ryvu Therapeutics SA
Responsible party
Sponsor
First posted
Jul 16, 2019
Start date
Sep 4, 2019
Primary completion
May 21, 2024
Completion
May 21, 2024
Last update
Sep 18, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SEL-120

Start the discussion